Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (75)

II-04Eleni Alexopoulou

Population pharmacokinetics of budesonide (BDS) and its two main metabolites 6β-hydroxy-budesonide(6OH-BDS) and 16α-hydroxy-prednisolone(16OH-PREDN) with and without hyperhydration effect

Wednesday 15:35-17:00

II-06Simon Arsène

In silico trials platform for exploration of trial design space in atopic dermatitis

Wednesday 15:35-17:00

II-07Peter Ashcroft

Mechanistic PKPD modelling of targeted protein degradation to improve compound selection in drug discovery and translation to the clinic

Wednesday 15:35-17:00

II-08Rami Ayoun Alsoud

Model-based interspecies scaling and impact of anti-drug antibodies on the pharmacokinetics of the therapeutic protein CB 4332

Wednesday 15:35-17:00

II-09Nicolas Azzopardi

Mechanistic model of oxytocin/vasopressin-stimulated GPCR.

Wednesday 15:35-17:00

II-11Pavel Balazki

4ß-OH Cholesterol as endogenous biomarker for CYP3A4 inducer DDI studies – a PBPK-QSP platform for in silico compound testing

Wednesday 15:35-17:00

II-12Catalina Barcelo

Use of informative prior distributions from mepolizumab data to support depemokimab PKPD model analysis

Wednesday 15:35-17:00

II-13Roberta Bartolucci

Exposure-Response Analysis of the Macitentan Effects on NT-proBNP and WHO functional class in adult patients with Pulmonary Arterial Hypertension

Wednesday 15:35-17:00

II-16Davide Bindellini

Understanding the physiology of the hypothalamic-pituitary-adrenal axis to optimise cortisol replacement therapy: A quantitative modelling framework

Wednesday 15:35-17:00

II-22Núria Buil Bruna

Understanding onset and extent of response using different clinical endpoints in Atopic Dermatitis

Wednesday 15:35-17:00

II-26JunSeok Cha

A Pharmacokinetic/Pharmacodynamic Model of Recombinant Batroxobin

Wednesday 15:35-17:00

II-28Wendy Chu

Disease-specific differences in pharmacokinetics of paromomycin and miltefosine between post-kala-azar dermal leishmaniasis and visceral leishmaniasis patients in Eastern Africa

Wednesday 15:35-17:00

II-30Michael Cloesmeijer

Physiologically-based pharmacokinetic modelling of recombinant factor IX Fc fusion protein (rFIXFc) and recombinant FIX (rFIX) to characterize extravasation and binding to type IV collagen

Wednesday 15:35-17:00

II-31Aude Coumau

Population pharmacokinetic modelling to characterize (es)citalopram exposure in a large cohort of psychiatric patients

Wednesday 15:35-17:00

II-34Anna Dari

Mechanistic Modeling Projections of Antibody Persistence After Homologous Booster Regimens of COVID-19 Vaccine Ad26.COV2.S in Humans

Wednesday 15:35-17:00

II-36Wilbert de Witte

Whole-body PBPK with tissue TMDD modelling to predict determining parameters of target occupancy in tissues

Wednesday 15:35-17:00

II-40Qian Dong

Population pharmacokinetic analysis of nonlinear behavior of adefovir

Wednesday 15:35-17:00

II-42Janna Duong

A dermal physiologically-based pharmacokinetic (PBPK) model of clobetasol propionate to predict systemic exposure in eczema and dermatitis patients

Wednesday 15:35-17:00

II-44Jacqueline Ernest

A translational site-of-action PK-PD modeling platform to propose treatment shortening regimens for tuberculosis

Wednesday 15:35-17:00

II-46Undine Falkenhagen

Can quantitative systems pharmacology guide precision dosing? An illustrative warfarin-INR example

Wednesday 15:35-17:00

II-47Alan Faraj

A model for evaluation of novel on-demand treatment of bleeding events in hemophilia subjects

Wednesday 15:35-17:00

II-48Anna Fochesato

A minimal PBPK model to unveil anti-tuberculosis drug distribution in pulmonary lesions: a blueprint for improving efficacy screenings.

Wednesday 15:35-17:00

II-49Sylvaine Galiegue

Derisking the development of rilzabrutinib, a BTK inhibitor currently in phase III, with a PBPK model in lieu of some clinical studies

Wednesday 15:35-17:00

II-50María García-Cremades

Risk stratification algorithm for MDR-TB patients based on pooled individual data analysis.

Wednesday 15:35-17:00

II-51Maite Garraza Obaldia

Semi-mechanistic model of the Haemodynamic effects of propofol and remifentanil administered in combination to patients undergoing general anaesthesia

Wednesday 15:35-17:00

II-52Frédéric Gaspar

Population pharmacokinetics of apixaban in a real-life hospitalized population

Wednesday 15:35-17:00

II-53Amira Ghoneim

Modeling of the Pharmacokinetics of the Selective Orexin-1 Receptor Antagonist ACT-539313 with Auto-Inhibition

Wednesday 15:35-17:00

II-54Audrick GIBERT

PK/PD of unfractionned heparin during cardiopulmonary bypass: an individual patient data meta-analysis of two studies

Wednesday 15:35-17:00

II-62Yannick Hoffert

An automated multi-model selection algorithm to improve precision dosing of tacrolimus in liver, lung, and bowel transplant recipients

Wednesday 15:35-17:00

II-63Ana Homšek

Population pharmacokinetic model of infliximab in patients with fistulising Crohn’s disease

Wednesday 15:35-17:00

II-64Vincent Hurez

Development of a primary Sjogren’s Syndrome (pSS) quantitative systems pharmacology (QSP) model linking mechanistic pathways to clinical scores.

Wednesday 15:35-17:00

II-69SEONGMEE JEONG

Human effective dose prediction of analgesic drug using translational PK-PD modeling

Wednesday 15:35-17:00

II-71Soo-Min Jung

Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis of Nesuparib (JPI-547) in Patients with Advanced Solid Tumor

Wednesday 15:35-17:00

II-73Atefeh Kazeroonian

A first-ever mechanistic disease model of IgG4-related disease identifies high-potential therapy targets

Wednesday 15:35-17:00

II-74heungjo Kim

Population pharmacokinetics of intravenous midazolam in critically ill patients supported with extracorporeal membrane oxygenation therapy

Wednesday 15:35-17:00

II-75Bastian Kister

Quantitative Systems Pharmacology of Interferon Alpha Administration and its induced cellular response in mice

Wednesday 15:35-17:00

II-76Christine Juliane Kleist

A PKPD model of favipiravir and ribavirin in Lassa virus infected mice

Wednesday 15:35-17:00

IV-17Jane Knöchel

Using semi-mechanistic modelling to inform the design of the Ph3 program for a novel PCSK9 antisense oligonucleotide

Thursday 15:25-16:55

IV-18Julia Korell

Population Pharmacokinetic Model for BI 1015550 in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis

Thursday 15:25-16:55

IV-20Shaun Kumar

Empirical Population Pharmacodynamic Models for beti-cel for the Treatment of Patients with β-Thalassemia who Require Regular Transfusions.

Thursday 15:25-16:55

IV-22Mun Kyungran

Development of User-Friendly Bayesian Predictive Platform for Blood Boron-10 Pharmacokinetics following Intravenous Infusion of [10B] L-4-BORONOPHENYLALANINE

Thursday 15:25-16:55

IV-23Jennifer Lang

Development of a semi-mechanistic pharmacokinetic/pharmacodynamic model of a small interfering RNA targeting liver proteins in mice and cynomolgus monkeys

Thursday 15:25-16:55

IV-27Moon Hee Lee

First-in-Human Dose Selection for TU7710 through Pharmacokinetic and Pharmacodynamic Modeling and Simulation

Thursday 15:25-16:55

IV-29Letao Li

Preeclampsia increases maternal exposure to betamethasone in pregnancy: a population pharmacokinetic study

Thursday 15:25-16:55

IV-31Hyeong-Seok Lim

Translational pharmacokinetic-pharmacodynamic modeling and simulation to predict efficacious human doses for YH35324 (GI-301)

Thursday 15:25-16:55

IV-32Klaus Lindauer

Allometric Scaling for Efficacious First-in-Human Dose Prediction of Pharmacologically-Active Parent and Metabolite Based on Rat, Dog and Monkey PK data

Thursday 15:25-16:55

IV-33Carolina Llanos-Paez

Extended model-based meta-analysis of joint longitudinal FEV1 and exacerbation rate in randomized COPD trials

Thursday 15:25-16:55

IV-36Julia Macente

Physiologically-based Pharmacokinetics modelling to predict the systemic exposure of medicines in infants via breastmilk: a contribution from the ConcePTION Project.

Thursday 15:25-16:55

IV-38Eleonora Marostica

Population PK/PD analysis for efgartigimod Phase 3 study in myasthenia gravis patients

Thursday 15:25-16:55

IV-43Nina Nauwelaerts

Physiologically Based Pharmacokinetic (PBPK) Modelling to Predict Human Milk Exposure to medicines: a contribution from the ConcePTION Project

Thursday 15:25-16:55

IV-47Marije Otto

Evaluation of Darigabat QTc Prolongation in Healthy Volunteers: a Concentration-QTcF Analysis

Thursday 15:25-16:55

IV-48Agustos Cetin Ozbey

Physiologically based pharmacokinetic modelling of the impact of hepatic impairment on glucuronidation – a case study with midazolam.

Thursday 15:25-16:55

IV-49Seongwon Park

Evidence-based evaluation for race difference of pirfenidone using population pharmacokinetics model

IV-50Suemin Park

Exposure-Response Analysis Using Time to Event Data for Bevacizumab Biosimilar, SB8 and the Reference Bevacizumab

Thursday 15:25-16:55

IV-52Blaise Pasquiers

Rituximab in Anti‑Neutrophil Cytoplasmic Antibodies (ANCA)-associated vasculitis: population pharmacokinetic modeling and simulations of alternative doses in under-exposed patients

Thursday 15:25-16:55

IV-53Christoph Pfaffendorf

A combined population pharmacokinetic model of proguanil and its active metabolite cycloguanil in infants to adults with uncomplicated malaria

Thursday 15:25-16:55

IV-55Thao- Nguyen Pham

Effect brain irradiation with X-ray/Proton beam on circulating immune cell in rodents: A longitudinal modeling approach

Thursday 15:25-16:55

IV-64Gledys Reynaldo Fernandez

Enlightenment the strategic selection of pegylated rHuEPO candidates using a mechanistic model- driven extrapolation approach of the pharmacokinetics and pharmacodynamics.

Thursday 15:25-16:55

IV-65Karine Rodriguez-Fernandez

Individualized dosing regimen optimization using a population pharmacokinetic-pharmacodynamic model for secukinumab in clinical practice psoriatic patients

Thursday 15:25-16:55

IV-68Medhat M. Said

Disease-drug-drug interaction in drug repurposing of intravenous imatinib for COVID-19 ARDS

Thursday 15:25-16:55

IV-69Eric Salgado

Target engagement analysis of belimumab in patients with systemic lupus erythematosus (SLE) and primary Sjogren’s syndrome (pSS)

Thursday 15:25-16:55

IV-71Darlene Santiago

External Validation of Population PK and PD Models for Characterizing the Impact of CYP2C9 and VKORC1 Genotypes in the Management of Warfarin Therapy in Caribbean Hispanic Patients.

Thursday 15:25-16:55

IV-76Stef Schouwenburg

A pooled population pharmacokinetic study of oral and intravenous clavulanic acid in neonates

Thursday 15:25-16:55

IV-80Carsten Terjung

Modeling PK and PK/PD in of anti-VEGF agents in a preclinical rabbit model of VEGF-induced retinal hyperpermeability

Thursday 15:25-16:55

IV-81Thi Quyen Tran

Model-based meta-analysis of relationship between pioglitazone and histological outcomes in non-alcoholic steatohepatitis patients

Thursday 15:25-16:55

IV-83Pieter Van Brantegem

Longitudinal time to positivity is unable to predict clinical outcome for drug susceptible tuberculosis

Thursday 15:25-16:55

IV-85Coen van Hasselt

Integrative pharmacokinetic model for esketamine and its metabolite esnorketamine

Thursday 15:25-16:55

IV-87Sander van Tilburg

Population pharmacokinetics and pharmacodynamics of intravenous immunoglobulin treatment in patients with Guillain-Barré syndrome

Thursday 15:25-16:55

IV-90Umberto Villani

Model-based rationale for the in vitro characterisation of antimicrobial combinations in Buruli Ulcer

Thursday 15:25-16:55

IV-92My Luong Vuong

Population pharmacokinetics of fluconazole in critically ill patients: an individual patient data meta-analysis.

Thursday 15:25-16:55

IV-93Zhigang Wang

A repeated time-to-event model linking infliximab clearance to the risk of relapse during maintenance treatment of patients with inflammatory bowel disease

Thursday 15:25-16:55

IV-95Shuying Yang

Population dose-Hgb modelling of Jesduvroq (daprodustat) across five phase 3 studies in chronic kidney disease patients with anemia

Thursday 15:25-16:55

IV-96Sung-yoon Yang

Prediction of potential drug-drug interaction of tofacitinib and ritonavir using a population modeling approach with allometric scaling method

Thursday 15:25-16:55

IV-97Janice Zhang

Mechanism-based pharmacokinetic-pharmacodynamic modeling of short-term erythroferrone response and long-term efficacy of erythropoietin in chemotherapy-induced anemia rats

Thursday 15:25-16:55

IV-98Qiaolin Zhao

Paracetamol (Acetaminophen) and Metabolites Population Pharmacokinetics Model in children and adults with Spinal Muscular Atrophy

Thursday 15:25-16:55